Veeva Systems (NYSE:VEEV) Partners With Flatiron To Enhance Clinical Trial Data Efficiency

Veeva Systems (NYSE:VEEV) experienced a 6% price increase last week, potentially propelled by its recent partnership with Flatiron Health. This collaboration aims to streamline clinical trial processes, integrating Flatiron's Clinical Pipe with Veeva's Electronic Data Capture system. Despite broader market declines influenced by U.S. export restrictions on tech to China, including a tech sell-off led by Nvidia and AMD, the alliance could have uplifted Veeva's shares, underscoring its growth prospects in healthcare technology. The broader market exhibited mixed movements, with energy stocks gaining while major tech indices fell.

Buy, Hold or Sell Veeva Systems? View our complete analysis and fair value estimate and you decide.

We've found 25 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Veeva Systems' recent partnership with Flatiron Health could significantly impact its growth narrative by reinforcing its position in healthcare technology. This collaboration aims to enhance clinical trial processes, potentially leading to increased client adoption and streamlined operations. However, the longer-term performance of Veeva shares tells a broader story. Over the past five years, the company achieved a total shareholder return of 26.37%, offering a long-term perspective on its growth and resilience. In contrast, Veeva outperformed the US Healthcare Services industry over the past year with a higher return, signifying investor confidence amid recent volatility.

Additionally, the integration with Flatiron Health may positively influence Veeva's revenue and earnings forecasts, as such innovations could attract more major pharma clients and support growth initiatives. Analysts currently project revenue to grow to $3.9 billion and earnings to reach $1.1 billion by 2028, highlighting potential sustained growth. With the recent price movement, Veeva's shares are approximately 21.4% below the consensus analyst price target of US$266.41, suggesting room for appreciation if growth expectations are met. This alignment with strategic partners like Flatiron Health could indeed play a crucial role in achieving these targets.

Click to explore a detailed breakdown of our findings in Veeva Systems' financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com